1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CSL Limited

CSL Limited

CSLLY
CSL LimitedUS flagOther OTC
21.35
USD
-0.21
- -
82.67BMarket Cap
CSL Limited
CSLLY
(Other OTC)

Recent

price

21.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.67
2.07
2.18
2.48
2.76
2.89
3.2
3.63
4.19
4.7
5.01
5.64
5.6
6.83
7.6
7.97
Revenue per Share
0.39
0.46
0.48
0.61
0.68
0.73
0.67
0.73
0.96
1.06
1.16
1.31
1.2
1.14
1.37
1.55
Basic EPS, GAAP
0.4
0.37
0.41
0.48
0.54
0.72
0.55
0.42
-0.55
-0.71
-0.75
-0.92
-0.67
-0.88
-0.65
-0.53
Free Cash Flow per Basic Share
0.16
0.22
0.21
0.25
0.27
0.28
0.31
0.33
0.37
0.45
0.49
0.53
0.55
0.64
0.66
0.74
Dividend per Share
1.67
2.01
1.95
1.22
1.25
1.29
1.29
1.58
2.13
2.77
3.41
4.26
7.46
7.85
8.58
9.46
Book Value per Share
1.22
1.35
1.27
1.08
1.16
0.96
0.88
1.16
1.26
1.86
2.42
3.14
6.37
0.72
1.58
2.7
Tangible Book Value per Share
2,267
2,162
2,077
1,994
1,935
1,887
1,848
1,821
1,809
1,812
1,815
1,819
1,875
1,929
1,932
1,936
Basic Weighted Avg Shares
3,787
4,476
4,537
4,950
5,335
5,459
5,910
6,616
7,588
8,510
9,100
10,265
10,493
13,174
14,690
15,430
Sales/Revenue/Turnover
24.01
21.79
20.16
22.92
23.86
26.07
17.11
19.66
23.14
24.68
24.68
25.23
22.07
15.96
18.82
19.18
Operating Margin (%)
133
178
176
202
195
181
220
161
297
375
420
495
542
831
938
1,017
Depreciation Expense
895
1,005
1,006
1,216
1,307
1,379
1,242
1,337
1,729
1,919
2,102
2,375
2,255
2,194
2,642
3,002
Net Income, GAAP
23.67
21.49
19.25
17.11
18.53
19.54
20.15
20.85
24.21
18.04
18.28
19.85
18.88
15.73
19.59
15.79
Effective Tax Rate (%)
23.63
22.46
22.16
24.57
24.5
25.26
21.02
20.22
22.78
22.55
23.1
23.14
21.49
16.65
17.99
19.46
Profit Margin (%)
2,169
1,941
2,517
2,353
2,362
2,321
2,444
2,989
3,079
3,266
4,305
4,286
9,352
4,651
5,818
7,035
Working Capital
371
203
1,130
1,673
1,885
2,278
3,081
3,853
4,161
4,242
5,790
5,333
5,164
11,172
11,239
10,694
LT Debt
3,582
3,895
3,509
3,007
3,162
2,747
2,567
3,164
4,080
5,251
6,527
8,381
14,578
17,826
19,401
21,407
Total Equity
15.1
17.79
15.66
19.19
20.71
22.15
14.57
15.53
16.58
18.23
16.01
15.22
9.67
6.47
7.16
7.67
Return on Invested Capital (%)
19.8
22.68
20.48
26.57
32.07
31.59
25.37
22.78
24.01
22.93
20.29
19.52
12.74
9.38
9.66
10.21
Return on Capital (%)
21.86
24.72
23.97
37.59
53.87
56.7
51.56
50.96
51.41
43.29
37.54
34.08
20.75
15.07
16.67
17.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.25%
28.76%
10.34%
Free Cash Flow
-25.78%
-2.49%
-19.16%
Net Income, GAAP
8.68%
7.85%
13.63%
Sales/Revenue/Turnover
11.11%
11.42%
5.04%
Total Cash Common Dividend
10.49%
10.33%
13.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
13,174
2024
- -
- -
- -
- -
14,690
2025
8,213
- -
- -
- -
15,430

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.14
2024
- -
- -
- -
- -
1.37
2025
1.04
- -
- -
- -
1.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.64
2024
- -
- -
- -
- -
0.66
2025
0.41
- -
- -
- -
0.74
Similar Companies
Enanta Pharmaceuticals, Inc. (ENTA)
enGene Holdings Inc. Warrants (ENGNW)
Initiator Pharma A/S (INIT.ST)
Revolution Medicines, Inc. (RVMD)
Mirxes Holding Company Limited (2629.HK)
Poolbeg Pharma PLC (POLB.L)
Business
CSL Limited is an Australian multinational biotechnology company that researches, develops, manufactures and markets biopharmaceutical products for rare and serious diseases, influenza vaccines and iron deficiency and nephrology therapies; it operates through CSL Behring, CSL Seqirus and CSL Vifor businesses, with CSL Plasma providing plasma collection oversight. CSL Behring offers plasma-derived and recombinant therapies including immunoglobulins such as PRIVIGEN and HIZENTRA for immunodeficiencies, haemophilia treatments like HEMGENIX gene therapy, hereditary angioedema prophylaxis such as ANDEMBRY (garadacimab), Alpha-1 antitrypsin therapies, and products for neurology, cardiovascular, respiratory and transplant areas; CSL Seqirus produces influenza vaccines including FLUAD for seniors and FLUCELVAX cell-based vaccines, plus pandemic preparedness solutions; CSL Vifor provides iron deficiency treatments like Ferinject and nephrology drugs such as FILSPARI for IgAN. Founded in 1916 and headquartered in Parkville, Melbourne, Australia, the company serves patients in more than 100 countries with manufacturing sites in the US, Europe, Australia and Asia Pacific, employing over 29,000 people. Recent developments include US$1.5 billion investment in US immunoglobulin manufacturing expansion announced in November 2025, a strategic collaboration with VarmX in September 2025 featuring a $2.1 billion acquisition option for VMX-C001 to reverse anticoagulant effects, announcement of CSL Seqirus demerger in August 2025 alongside 3,000 non-US job cuts targeting $550 million annual savings, approvals and launches of ANDEMBRY in multiple markets including the US and Japan, conversion of FILSPARI conditional approval to full EU marketing authorisation in April 2025, R&D site consolidation to six global hubs, and combination of Behring and Vifor commercial functions to streamline operations.

Company News

APIChatGPT

  • prnewswire.com

    CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

  • globenewswire.com

    CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

  • reuters.com

    Australia says CSL unit Seqirus to discontinue Benpen injections from November

  • seekingalpha.com

    CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise

  • zacks.com

    Should Value Investors Buy CSL Limited (CSLLY) Stock?

  • zacks.com

    CSLLY vs. ACAD: Which Stock Is the Better Value Option?

  • seekingalpha.com

    Carlisle Companies: Resilient In Challenging Sector Backdrop

  • zacks.com

    CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?

  • zacks.com

    CSLLY or ARGX: Which Is the Better Value Stock Right Now?

  • zacks.com

    CSLLY vs. ARGX: Which Stock Is the Better Value Option?

  • defenseworld.net

    Analyzing CSL (OTCMKTS:CSLLY) and Ascentage Pharma Group International (NASDAQ:AAPG)

  • prnewswire.com

    CSL announces expansion of Illinois plasma therapy manufacturing facility

  • zacks.com

    CSLLY or EXAS: Which Is the Better Value Stock Right Now?

  • reuters.com

    CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease

  • zacks.com

    CSLLY vs. EXAS: Which Stock Is the Better Value Option?

  • zacks.com

    CSL Limited (CSLLY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  • seekingalpha.com

    CSL Limited (CSLLY) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    CSL Limited (CSLLY) Discusses Leadership Transition and Appointment of Interim CEO Transcript

  • zacks.com

    CSLLY or TECH: Which Is the Better Value Stock Right Now?